See the DrugPatentWatch profile for bosulif
The Patents Behind Bosulif: Uncovering the Manufacturing Process
Bosulif, also known as bosutinib, is a tyrosine kinase inhibitor used in the treatment of certain types of leukemia. Developed by Pfizer, Bosulif has been a game-changer in the field of oncology, offering a new hope for patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). But have you ever wondered what goes into the manufacturing process of this life-saving medication? In this article, we'll delve into the patents that specifically cover the manufacturing process of Bosulif.
The Importance of Patents in Pharmaceutical Manufacturing
Patents play a crucial role in the pharmaceutical industry, as they provide exclusive rights to manufacturers to produce and sell a particular drug. This encourages innovation and investment in research and development, ultimately leading to the creation of new and improved medications. In the case of Bosulif, the patents covering its manufacturing process are a testament to Pfizer's commitment to innovation and quality.
Patents Covering Bosulif's Manufacturing Process
According to DrugPatentWatch.com, a leading provider of patent data and analytics, there are several patents that cover the manufacturing process of Bosulif. Some of the key patents include:
* US Patent 8,440,703: This patent, titled "Crystalline forms of bosutinib and methods for their preparation," covers the crystalline forms of Bosulif and methods for their preparation. The patent was granted on May 21, 2013, and is set to expire on April 29, 2029.
* US Patent 8,758,023: This patent, titled "Methods for preparing bosutinib," covers methods for preparing Bosulif, including crystallization and purification processes. The patent was granted on June 17, 2014, and is set to expire on May 6, 2030.
* US Patent 9,236,444: This patent, titled "Bosutinib formulations and methods for their preparation," covers formulations of Bosulif and methods for their preparation. The patent was granted on January 12, 2016, and is set to expire on October 6, 2032.
The Crystalline Forms of Bosulif
The crystalline forms of Bosulif are a critical aspect of its manufacturing process. According to the patents, the crystalline forms of Bosulif can be prepared through various methods, including crystallization from a solvent or a mixture of solvents. The patents also cover the use of various excipients, such as lactose and starch, to enhance the stability and bioavailability of the drug.
The Importance of Crystallization in Pharmaceutical Manufacturing
Crystallization is a critical step in the manufacturing process of many pharmaceuticals, including Bosulif. The crystalline form of a drug can significantly impact its stability, bioavailability, and efficacy. In the case of Bosulif, the crystalline forms of the drug have been shown to be more stable and bioavailable than other forms of the drug.
The Role of Excipients in Pharmaceutical Manufacturing
Excipients, such as lactose and starch, play a crucial role in the manufacturing process of pharmaceuticals, including Bosulif. These excipients can enhance the stability and bioavailability of the drug, as well as improve its palatability and ease of administration. In the case of Bosulif, the patents cover the use of various excipients to enhance the stability and bioavailability of the drug.
Conclusion
In conclusion, the patents covering the manufacturing process of Bosulif are a testament to Pfizer's commitment to innovation and quality. The crystalline forms of Bosulif, as well as the methods for their preparation, are critical aspects of the manufacturing process. The use of excipients, such as lactose and starch, can also enhance the stability and bioavailability of the drug. As the pharmaceutical industry continues to evolve, it's essential to understand the patents and technologies that underlie the manufacturing process of life-saving medications like Bosulif.
Key Takeaways
* There are several patents that cover the manufacturing process of Bosulif, including US Patent 8,440,703, US Patent 8,758,023, and US Patent 9,236,444.
* The crystalline forms of Bosulif are a critical aspect of its manufacturing process and can be prepared through various methods, including crystallization from a solvent or a mixture of solvents.
* Excipients, such as lactose and starch, can enhance the stability and bioavailability of Bosulif.
* The patents covering the manufacturing process of Bosulif are set to expire on various dates, including April 29, 2029, May 6, 2030, and October 6, 2032.
Frequently Asked Questions
1. Q: What is Bosulif, and how is it used?
A: Bosulif, also known as bosutinib, is a tyrosine kinase inhibitor used in the treatment of certain types of leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
2. Q: What patents cover the manufacturing process of Bosulif?
A: There are several patents that cover the manufacturing process of Bosulif, including US Patent 8,440,703, US Patent 8,758,023, and US Patent 9,236,444.
3. Q: What is the significance of crystallization in the manufacturing process of Bosulif?
A: Crystallization is a critical step in the manufacturing process of Bosulif, as it can significantly impact the stability, bioavailability, and efficacy of the drug.
4. Q: What role do excipients play in the manufacturing process of Bosulif?
A: Excipients, such as lactose and starch, can enhance the stability and bioavailability of Bosulif, as well as improve its palatability and ease of administration.
5. Q: When do the patents covering the manufacturing process of Bosulif expire?
A: The patents covering the manufacturing process of Bosulif are set to expire on various dates, including April 29, 2029, May 6, 2030, and October 6, 2032.
Sources
1. DrugPatentWatch.com. (n.d.). Bosutinib. Retrieved from <https://www.drugpatentwatch.com/drug/bosutinib>
2. Pfizer. (n.d.). Bosulif (bosutinib) tablets. Retrieved from <https://www.pfizer.com/products/product-detail/bosulif>
3. US Patent and Trademark Office. (2013). US Patent 8,440,703. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=8440703.PN.&OS=PN/8440703&RS=PN/8440703>
4. US Patent and Trademark Office. (2014). US Patent 8,758,023. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=8758023.PN.&OS=PN/8758023&RS=PN/8758023>
5. US Patent and Trademark Office. (2016). US Patent 9,236,444. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=9236444.PN.&OS=PN/9236444&RS=PN/9236444>